Latest Eyesight News

Got Old Eyeglasses?

                    Vision Source is Collecting Used Eyeglasses for Holiday Project

All Glasses Collected in December will go to a Medical Mission in Mexico

 

Tulsa, OK – If you have an old pair of unused eyeglasses or if new glasses are on your Christmas gift list, you can help someone in need by taking them to Vision Source of Greater Tulsa. During the month of December, Optometrists at eleven local Vision Source offices are collecting eyeglasses for an upcoming medical mission trip sponsored by Asbury United Methodist Church.

Dr. Terry Lawson, Dr. Gerri Lawson, and Dr. Cheri Watkins have participated in Asbury medical mission trips for many years. The eye doctors travel with the church to remote locations in Mexico where they examine the vision of those who don’t receive medical care. The recycled eyeglasses are distributed to help people in need see clearly.

Mary Ann Smith, director of global outreach for Asbury, said during the medical missions, there is pure joy on people’s face when they put on the eyeglasses.

“It’s particularly dramatic for children and young people who have quite impaired vision to be able to see for the first time,” she said. “It’s really wonderful when we can get them eyeglasses.”

Optometrists from Vision Source of Greater Tulsa are asking the community to drop off old eyeglasses at any of their eleven Vision Source clinics in the Greater Tulsa Area.

Bixby

Dr. David Hall & Dr. James Ward

12345 S. Memorial, Suite 118

 

Broken Arrow

Dr. Brad Wells

2412 West Detroit Street

Dr. Scott Hibbetts

433 Stone Wood Drive

 

Jenks

Dr. Tammy Paul

524 East Main Street

 

 

Owasso

Dr. Denise Johnson

8430 N 123 East Avenue

Sand Springs

Dr. Larry Higgs & Dr. Dennis Morris

101 West 41st Street

Sapulpa

Dr. Larry Higgs & Dr. Dennis Morris

Tulsa

Terry L. Lawson, Dr. Gerri Lawson & Dr. Cheri Watkins

9102 S. Toledo

 

Dr. Denise L. Roddy

5986 S. Yale

Dr. David Free

1223S. Peoria, Suite A

Dr. DJ Riner

9720 East 31st Street                               

 

For more information or to talk with a Vision Source optometrist about the used eyeglasses program, contact Diane White at 918-794-3555.

            

 About Vision Source

Vision Source is a network of premier eye doctors that are conveniently located throughout the metro Tulsa area.  For a complete listing, visit www.visionsource-Tulsaok.com

                                                                    

 

November 18, 2009

For Immediate Release:

November is American Diabetes Month – Tips for prevention 

Tulsa, OK – November is American Diabetes Month and the Optometrists at Vision Source of Greater Tulsa warn that people living with diabetes are at risk for developing eye disease. Diabetes is the leading cause of new cases of blindness among adults aged 20 to 74 years, according to the American Diabetes Association. 

The American Diabetes Association recommends those living with diabetes to see their eye care professional at least once a year for an annual dilated eye exam.

Vision Source of Greater Tulsa recommends that you see your eye care professional if the following symptoms occur:

  • Your vision becomes blurry
  • You have trouble reading signs or books
  • You see double
  • One or both of your eyes hurt
  • Your eyes get red and stay that way
  • You feel pressure in your eye
  • You see spotters or floaters
  • Straight lines do not look straight

There are steps to take to protect your eyes if you are diabetic.

–          Blood sugar levels must be kept under tight control.

–          High blood sugar may make your vision temporarily blurry.

–          Studies have shown the better control of blood sugar slows the onset and progression of diabetic eye disease.

___________________________________________

eyeglassesTUESDAY, Aug. 4 (HealthDay News) — A new type of eye drop appears to protect retinal and optic nerve cells — and even reverse some sight loss — in patients battling glaucoma, a leading cause of blindness, new research suggests.

Italian researchers found that the topical use of nerve growth factor, which is easily absorbed by the eye in drop form, spares retinal ganglion cells from nerve damage caused by the build-up of eye pressure associated with glaucoma.

This is “the first evidence that nerve growth factor eye drops may represent a potential treatment for glaucoma,” said Dr. Stefano Bonini, professor and chairman of the department of ophthalmology at the University of Rome Campus Bio-Medico.

Bonini and his team reported their findings in the Aug. 3 online edition of the Proceedings of the National Academy of Sciences.

Glaucoma is an often symptom-less grouping of incurable, but treatable, eye diseases that cause vision loss and blindness as a result of slowly building damage to the eye’s optic nerve, according to the Glaucoma Research Foundation.

Although people of all ages are vulnerable to the disease, the elderly face a particularly high risk. The Glaucoma Research Foundation notes that glaucoma is the second most common cause of blindness worldwide. About 4 million Americans have the disease (about half don’t know it), and roughly 120,000 have lost their vision as a result. In sum, glaucoma accounts for roughly 10% of all blindness in the United States.

Although current interventions can reduce the troublesome eye pressure associated with glaucoma, thereby slowing its progression, no treatment to date has succeeded in restoring vision lost to the disease.

Exploring ways to do that, the authors observed that nerve growth factor — a protein found in human tissue — previously had been shown to be beneficial when treating the brain tissue of Parkinson’s and Alzheimer’s patients. Because of similarities in development, glaucoma is sometimes called “the ocular Alzheimer’s disease,” they noted.

The current work focused on using nerve growth factor in eye drops to treat dozens of rats in whom glaucoma was induced.

Testing two different amounts of nerve growth factor, the team documented a significant drop in the rate of retinal cell death, particularly with the higher dose.

The authors then tested the nerve growth factor eye drops on three patients with advanced glaucoma, each of whom had suffered significant visual deterioration.

A battery of eye function tests conducted before treatment with nerve growth factor eye drops, three months after treatment began and three months post-treatment demonstrated that the vision of two of the patients actually improved, while the vision of the third patient stabilized following treatment.

Furthermore, the observed improvements in visual field, optic nerve function, contrast sensitivity and visual acuity remained in place 18 months after the first eye drops were administered, the researchers reported.

Despite the encouraging results, Bonini cautioned that the novel nerve growth factor approach to halting glaucoma disease will not be available to consumers in the immediate future.

“These impressive findings are promising, but still far from any broad clinical application, since nerve growth factor is not currently available for clinical use,” said Bonini. “And these pilot clinical results should be confirmed in large clinical trials.

But the study team suggested that the findings could theoretically pave the way for new options in treating eye disease and a range of other neurodegenerative diseases.

Rando Allikmets, a professor of ophthalmology, pathology and cell biology at Columbia University in New York City, applauded the research team for its effort to develop a better treatment for glaucoma.

“The science concerning glaucoma is very much less clear than, say, that regarding age-related macular degeneration,” he said. “So it is true that there are some treatments for glaucoma, and they are sometimes effective at slowing down or delaying the progress of the disease,” Allikmets noted.

“But that’s it. The available drugs don’t get at the actual disease,” he added. “So it’s not clear if this work will hold up under further study, but if these researchers were able to actually reverse some of the actual vision loss due to glaucoma that would be a very strong statement.”

SOURCE: Stefano Bonini, department of ophthalmology, University of Rome Campus Bio-Medico, Italy; Rando Allikmets, Ph.D., the William and Donna Acquavella associate professor of ophthalmology, director of Molecular Genetics Laboratory, Columbia University, New York City; Aug. 3, 2009, Proceedings of the National Academy of Sciences, online

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Trackback this post  |  Subscribe to the comments via RSS Feed


%d bloggers like this: